# Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions

> **NCT05096442** · NA · COMPLETED · sponsor: **Genoss Co., Ltd.** · enrollment: 204 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** GENOSS® DCB
- **DEVICE:** SeQuent® Please NEO

## Key facts

- **NCT ID:** NCT05096442
- **Lead sponsor:** Genoss Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2023-06-28
- **Final completion:** 2023-11-21
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096442, "Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05096442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*